Calyxt, a developer of gene-edited crop traits spun out of Cellectis, announced terms for its IPO on Monday. The New Brighton, MN-based company plans to raise $100 million by offering 6.06 million shares at a price range of $15 to $18. Parent Cellectis may...read more
Galapagos, a Belgian biotech developing new treatments for inflammatory diseases, announced terms for its IPO on Tuesday. The Mechelen, Belgium-based company plans to raise $160 million by offering 3.78 million ADSs. Its shares are currently listed on...read more
Four companies publicly listed on US markets during the last full week of the first quarter, raising $510 million. Solar tech provider SolarEdge outshined its peers while mega biotech Cellectis saw speculators jump in before the IPO and then quickly jump...read more
Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T cells, raised $229 million in an upsized IPO by offering 5.5 million ADSs (all primary) at $41.50. The Paris, France-based company had planned to offer 4.8 million ADSs, upwardly...read more
Cream of the gene-edited crop: Calyxt sets terms for $100 million IPO
Calyxt, a developer of gene-edited crop traits spun out of Cellectis, announced terms for its IPO on Monday. The New Brighton, MN-based company plans to raise $100 million by offering 6.06 million shares at a price range of $15 to $18. Parent Cellectis may...read more
Survival of the fittest biotechs: Galapagos sets terms for $160 million US IPO
Galapagos, a Belgian biotech developing new treatments for inflammatory diseases, announced terms for its IPO on Tuesday. The Mechelen, Belgium-based company plans to raise $160 million by offering 3.78 million ADSs. Its shares are currently listed on...read more
US IPO Weekly Recap: SolarEdge shines while other IPOs fall flat
Four companies publicly listed on US markets during the last full week of the first quarter, raising $510 million. Solar tech provider SolarEdge outshined its peers while mega biotech Cellectis saw speculators jump in before the IPO and then quickly jump...read more
Cellectis prices upsized IPO at $41.50, selling 750k additional ADSs over upwardly revised deal size
Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T cells, raised $229 million in an upsized IPO by offering 5.5 million ADSs (all primary) at $41.50. The Paris, France-based company had planned to offer 4.8 million ADSs, upwardly...read more